drugset / Trial / NCT01334099
Safety Study of Radiation and CP-675,206 Infusion for Breast Cancer Patients
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the maximum dose of CP-675,206 when given in combination with radiation. Patients will be given local radiation to one tumor site and an intravenous infusion of CP-675,206.
Timeline
- Start
- 2010-07
- Primary completion
- 2013-03
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tremelimumab | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | Tremelimumab | Monoclonal antibody | 6 mg/kg | Intravenous |
| Subject | Tremelimumab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Tremelimumab | Monoclonal antibody | 15 mg/kg | Intravenous |